<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197050</url>
  </required_header>
  <id_info>
    <org_study_id>2019-11-01R</org_study_id>
    <nct_id>NCT04197050</nct_id>
  </id_info>
  <brief_title>Effect of Sacubitril/Valsartan on Reduced Right Ventricular Ejection Fraction in Patients With CTD</brief_title>
  <acronym>EARLY-MYO-CTD</acronym>
  <official_title>Effect of Sacubitril/Valsartan on Right Ventricular Dysfunctioning Patients With Connective Tissue Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure, one of the leading causes of connective tissue disease (CTD) mortality, has
      attracted increasing attention. Currently, no known study had focused on the effect of
      sacubitril/valsartan on right ventricular dysfunction and in the systemic disease induced
      heart disease. We aimed to observe the effect of sacubitril/valsartan on primary endpoints (6
      minutes walking test and myocardial fibrosis) in CTD patients with right ventricular ejection
      fraction reduction (RV-HFrEF).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with CTD frequently exhibit multi-organ pathophysiological and functional damage.
      Heart failure, one of the leading causes of CTD mortality, has attracted increasing
      attention. Mostly, patients with CTD present with nonspecific cardiac symptoms, normal ECG,
      and preserved left ventricular ejection fraction (LVEF) and therefore do not receive an early
      cardiac diagnosis and treatment. Pulmonary arterial hypertension (PAH), right ventricular
      (RV) dilatation and hypertrophy might become the first and the most frequent cardiac
      findings. Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitors, is a
      &quot;superstar&quot; which inhibits both neprilysin and renin-angiotensin aldosterone system that
      closely related to the heart failure mechanism. It has been strongly recommended as class I
      drug in treating the patient with chronic HFrEF from 2017 ACC/AHA/HFSA heart failure
      guideline for the ability of dramatically reduce the cardiovascular mortality rate.

      Cardiovascular magnetic resonance (CMR) is able to depict myocardial characteristics from
      structure to tissue properties using cine and late gadolinium enhancement (LGE) sequences.
      Newly developed imaging studies to date include T1 mapping and T1-derived extracellular
      volume estimation. All the previous studies in CTD have been restricted to patients with
      advanced cardiac involvement.

      Together with clinical assessment and multi-imaging tests, the aim of the present study is
      going to observe the effect of sacubitril/valsartan on primary endpoints (6 minutes walking
      test and myocardial fibrosis) in CTD patients with RV-HFrEF.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 20, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exercise tolerance</measure>
    <time_frame>change between 1 and 6 months after treatment</time_frame>
    <description>6 minutes walking test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrosis Assessment</measure>
    <time_frame>change between 1 and 6 months after treatment</time_frame>
    <description>LGE assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fibrosis Assessment</measure>
    <time_frame>change between 1 and 6 months after treatment</time_frame>
    <description>ECV quantification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CTD activity</measure>
    <time_frame>change between 1 and 6 months after treatment</time_frame>
    <description>antinuclear antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality Rate</measure>
    <time_frame>change between 1 and 6 months after treatment</time_frame>
    <description>all cause of death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Myocardial Injury</condition>
  <condition>Connective Tissue Diseases</condition>
  <arm_group>
    <arm_group_label>sacubitril/valsartan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. sacubitril/valsartan will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The diagnosis of CTD was made based on the clinical classification criteria. The patient was diagnosed by an echocardiography demonstration, when RVEF is suggested lower or equal to 45%, the patient will be considered a candidate after consent is signed. Valsartan will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril / Valsartan Oral Tablet</intervention_name>
    <description>After recruiting participants and collecting the baseline information, sacubitril/valsartan group will receive sacubitril/valsartan and optimal pharmaceutical treatment (OPT). The control group will receive valsartan and OPT. A CMR scan and a post-processed imaging procedure will later be carried on in order to detect the cardiac impairment.</description>
    <arm_group_label>sacubitril/valsartan group</arm_group_label>
    <other_name>CMR examination</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18-75 years old.

          -  confirmed CTD（including systemic lupus erythematosus, myositis, polymyositis, systemic
             sclerosis, sarcoid, Sjögren's syndrome or mixed connective tissue disease）

          -  SLEDAI ≤ 6 in patients with SLE or ESR ≤ 30 in patients with SSc

          -  already have OPT for CTD at least 3 month

          -  RVEF ≤ 45%

          -  Providing written informed consent

        Exclusion Criteria:

          -  Documented coronary artery disease or prior angiography for coronary artery disease
             (&gt;50% stenosis).

          -  Patients with known congenital heart disease or other systemic diseases that might
             induce RVrEF.

          -  Patients with standard metallic contraindications to CMR or an estimated glomerular
             filtration rate &lt; 30 ml/min/1.73 m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng Jiang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital, School of Medicine, Shanghai Jiantong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meng Jiang, MD</last_name>
    <phone>+86 13788912766</phone>
    <email>jiangmeng0919@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Braun J, Krüger K, Manger B, Schneider M, Specker C, Trappe HJ. Cardiovascular Comorbidity in Inflammatory Rheumatological Conditions. Dtsch Arztebl Int. 2017 Mar 24;114(12):197-203. doi: 10.3238/arztebl.2017.0197. Review.</citation>
    <PMID>28407841</PMID>
  </reference>
  <reference>
    <citation>Leal GN, Silva KF, França CM, Lianza AC, Andrade JL, Campos LM, Bonfá E, Silva CA. Subclinical right ventricle systolic dysfunction in childhood-onset systemic lupus erythematosus: insights from two-dimensional speckle-tracking echocardiography. Lupus. 2015 May;24(6):613-20. doi: 10.1177/0961203314563135. Epub 2014 Dec 8.</citation>
    <PMID>25492941</PMID>
  </reference>
  <reference>
    <citation>Hassoun PM. The right ventricle in scleroderma (2013 Grover Conference Series). Pulm Circ. 2015 Mar;5(1):3-14. doi: 10.1086/679607. Review.</citation>
    <PMID>25992267</PMID>
  </reference>
  <reference>
    <citation>Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum. 2005 Jul;52(7):2125-32.</citation>
    <PMID>15986394</PMID>
  </reference>
  <reference>
    <citation>Argula RG, Karwa A, Lauer A, Gregg D, Silver RM, Feghali-Bostwick C, Schanpp LM, Egbert K, Usher BW, Ramakrishnan V, Hassoun PM, Strange C. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2017 May;14(5):682-689. doi: 10.1513/AnnalsATS.201608-655OC.</citation>
    <PMID>28282243</PMID>
  </reference>
  <reference>
    <citation>Rich S, Pogoriler J, Husain AN, Toth PT, Gomberg-Maitland M, Archer SL. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest. 2010 Nov;138(5):1234-9. doi: 10.1378/chest.09-2815.</citation>
    <PMID>21051399</PMID>
  </reference>
  <reference>
    <citation>van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011 Dec 6;58(24):2511-9. doi: 10.1016/j.jacc.2011.06.068.</citation>
    <PMID>22133851</PMID>
  </reference>
  <reference>
    <citation>Guo Q, Wu LM, Wang Z, Shen JY, Su X, Wang CQ, Gong XR, Yan QR, He Q, Zhang W, Xu JR, Jiang M, Pu J. Early Detection of Silent Myocardial Impairment in Drug-Naive Patients With New-Onset Systemic Lupus Erythematosus: A Three-Center Prospective Study. Arthritis Rheumatol. 2018 Dec;70(12):2014-2024. doi: 10.1002/art.40671.</citation>
    <PMID>30070061</PMID>
  </reference>
  <reference>
    <citation>Owens AT, Brozena S, Jessup M. Neprilysin Inhibitors: Emerging Therapy for Heart Failure. Annu Rev Med. 2017 Jan 14;68:41-49. doi: 10.1146/annurev-med-052915-015509. Epub 2016 Sep 21. Review.</citation>
    <PMID>27686019</PMID>
  </reference>
  <reference>
    <citation>McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993-1004. doi: 10.1056/NEJMoa1409077. Epub 2014 Aug 30.</citation>
    <PMID>25176015</PMID>
  </reference>
  <reference>
    <citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017 Aug 8;136(6):e137-e161. doi: 10.1161/CIR.0000000000000509. Epub 2017 Apr 28. Review.</citation>
    <PMID>28455343</PMID>
  </reference>
  <reference>
    <citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. Erratum in: Eur Heart J. 2016 Dec 30;:.</citation>
    <PMID>27206819</PMID>
  </reference>
  <reference>
    <citation>Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11. Erratum in: N Engl J Med. 2019 Mar 14;380(11):1090.</citation>
    <PMID>30415601</PMID>
  </reference>
  <reference>
    <citation>Pascual-Figal D, Wachter R, Senni M, Belohlavek J, Noè A, Carr D, Butylin D. Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan. ESC Heart Fail. 2018 Apr;5(2):327-336. doi: 10.1002/ehf2.12246. Epub 2017 Dec 14.</citation>
    <PMID>29239515</PMID>
  </reference>
  <reference>
    <citation>Jiang M, Wang Z, Su X, Gong X, Pu J, Wu L, Liu C, Yao Q, Kong L, Xu J, He B. The Significance of Interstitial Fibrosis on Left Ventricular Function in Hypertensive versus Hypertrophic Cardiomyopathy. Sci Rep. 2018 Jul 3;8(1):9995. doi: 10.1038/s41598-018-27049-1. Erratum in: Sci Rep. 2018 Aug 10;8(1):12232.</citation>
    <PMID>29968754</PMID>
  </reference>
  <reference>
    <citation>Jiang M, Xu J, He B. Diffuse Epicardial Involvement on Cardiac Magnetic Resonance Imaging. JAMA Cardiol. 2016 Oct 1;1(7):845-846. doi: 10.1001/jamacardio.2016.2557.</citation>
    <PMID>27579709</PMID>
  </reference>
  <reference>
    <citation>Jiang M, Pu J, Yao J, Xu J, He B. An acromegaly-induced cardiomyopathy mimicking amyloidosis: (Manifestation of acromegaly-induced-cardiomyopathy). Int J Cardiol. 2016 Jul 15;215:60-1. doi: 10.1016/j.ijcard.2016.04.043. Epub 2016 Apr 13.</citation>
    <PMID>27111161</PMID>
  </reference>
  <reference>
    <citation>Leng S, Jiang M, Zhao XD, Allen JC, Kassab GS, Ouyang RZ, Tan JL, He B, Tan RS, Zhong L. Three-Dimensional Tricuspid Annular Motion Analysis from Cardiac Magnetic Resonance Feature-Tracking. Ann Biomed Eng. 2016 Dec;44(12):3522-3538. Epub 2016 Jul 19.</citation>
    <PMID>27436293</PMID>
  </reference>
  <reference>
    <citation>Wu LM, An DL, Yao QY, Ou YZ, Lu Q, Jiang M, Xu JR. Hypertrophic cardiomyopathy and left ventricular hypertrophy in hypertensive heart disease with mildly reduced or preserved ejection fraction: insight from altered mechanics and native T1 mapping. Clin Radiol. 2017 Oct;72(10):835-843. doi: 10.1016/j.crad.2017.04.019. Epub 2017 May 25.</citation>
    <PMID>28552325</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>January 4, 2020</last_update_submitted>
  <last_update_submitted_qc>January 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Connective Tissue Diseases</keyword>
  <keyword>sacubitril/valsartan</keyword>
  <keyword>Cardiovascular Magnetic Resonance</keyword>
  <keyword>Extracellular Volume</keyword>
  <keyword>exercise tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

